Sacituzumab govitecan failed to extend PFS in patients with hormone receptor-positive, HER2-negative breast cancer following ...

Elacestrant combined with everolimus or abemaciclib showed significant PFS benefits in ER-positive, HER2-negative metastatic breast cancer patients. The ELEVATE trial reported median PFS of 8.3 months ...

There has been an explosion of newer HER2-directed therapies, including monoclonal antibodies, novel antibody-drug conjugates ...

Notably, the benefit was consistent across all prespecified subgroups, including premenopausal status and prior chemotherapy. Secondary end points also favored giredestrant, with a 31% reduction in ...

So in summary, HER2CLIMB-05 was a positive study. It showed that adding tucatinib for both HR-positive as well as HR-negative ...

Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or ...

Breast cancer is a complex disease with numerous classifications. Understanding risk factors such as age, family history, genetic mutations such as breast cancer gene 1/breast cancer gene 2 ...

Enhertu showed improved iDFS over Kadcyla in early-stage HER2-positive breast cancer with residual disease post-neoadjuvant ...

Medically reviewed by Marla Anderson, MD If you have HER2-positive breast cancer, your options for treatment will depend on ...

“Medical Journeys” is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...